650E2-2B12, CMCC #10121 (IVI 10083) (ATCC® HB-10812)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type:: hybridoma: B lymphocyte; somatic cell hybri  /  Tissue: spleen  / 

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Tissue spleen
Cell Type hybridoma: B lymphocyte; somatic cell hybri
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Age adult
Strain BALB/c
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Tumorigenic Yes
Effects
Yes, BALB/c and (C57BL/6 X BALB/c)F1 mice
Complete Growth Medium Modified MA plus 10% fetal bovine serum.
Complete Growth Medium
Depositor's culture medium: Modified MA plus 10% fetal bovine serum.
Culture Conditions
Temperature: 37.0°C
Isotype IgG1
Name of Depositor Cetus Corp.
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Ring DB, et al. Monoclonal anti-human breast cancer antibodies. US Patent 5,629,197 dated May 13 1997

Ring DB. Antigen-binding sites of antibody molecules specific for cancer antigens. US Patent 6,054,561 dated Apr 25 2000

Basic Documentation
References

Ring DB, et al. Monoclonal anti-human breast cancer antibodies. US Patent 5,629,197 dated May 13 1997

Ring DB. Antigen-binding sites of antibody molecules specific for cancer antigens. US Patent 6,054,561 dated Apr 25 2000